+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Treatment of multiple myeloma with intravenous pamidronate. Pain prevention and suppression of hypercalcemia risk

Treatment of multiple myeloma with intravenous pamidronate. Pain prevention and suppression of hypercalcemia risk

Medicina 64(4): 289-294

In a prospective clinical study, with the patient as its own control, we selected patients with stage III multiple myeloma. We treated them monthly with intravenous (i.v.) Disodic Pamidronate: 90 mg in 2 to 21 cycles. Four patients died during the study. The remaining 13 patients presented reduced bone resorption urinary markers (D-Pyr mainly) as well as urinary calcium (bone turnover reduction). Both effects (metabolic interchange reduction and calcium variation) did not show a direct relationship, being the 1st magnitude proportional to the baseline level and the 2nd independent from it. We noted pain reduction (VAS: visual analogs scale), low analgesic consumption, and the absence of future skeletal problems. The treatment tolerance was good. All these factors contribute to justify the welfare of the patient demonstrated by ECOG (Eastern Cooperative Oncology Group), not only improving the average results but also extending this improvement to future results. Our observation suggests that under strict procedures, this treatment could be very adequate in patients with advanced multiple myeloma independent of the state of the disease at the beginning of the study.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 050843212

Download citation: RISBibTeXText

PMID: 15338969

Related references

Intravenous pamidronate in the treatment of severe idiopathic infantile hypercalcemia. Iranian Journal of Kidney Diseases 7(2): 160-164, 2013

Rapid pain relief and marked sclerotic change of multiple bone metastases from a synovial sarcoma after treatment with intravenous pamidronate and chemotherapy. Journal of Orthopaedic Science 14(2): 224-227, 2009

Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages. American Journal of Medicine 95(3): 297-304, 1993

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. Journal of Clinical Oncology 16(2): 593-602, 1998

Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth?. International Journal of Technology Assessment in Health Care 15(1): 108-122, 1999

Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma. Hang Tian Yi Xue Yu Yi Xue Gong Cheng 15(5): 377-378, 2002

Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Archives of Internal Medicine 154(17): 1935-1944, 1994

True nonsecretory multiple myeloma in a patient presenting with hypercalcemia and bone pain. Blood 96(11 Part 2): 278b, November 16, 2000

Intravenous pamidronate in the treatment and prevention of osteoporosis. Internal Medicine Journal 34(4): 162-166, 2004

Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism. Southern Medical Journal 89(6): 637-640, 1996

Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. Medical Science Monitor 8(4): Pi31-Pi36, 2002

Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. American Journal of Clinical Oncology 28(1): 8-16, 2005

Intravenous pamidronate sodium therapy in immobilization-related hypercalcemia. Clinical Nephrology 43(2): 138-139, 1995